Cameron Turtle Sells 15,000 Shares of Spyre Therapeutics (NASDAQ:SYRE) Stock

Spyre Therapeutics, Inc. (NASDAQ:SYRE) CEO Cameron Turtle sold 15,000 shares of the company’s stock in a transaction on Monday, June 1st. The stock was sold at an average price of $70.43, for a total value of $1,056,450.00. Following the transaction, the chief executive officer owned 597,540 shares in the company, valued at $42,084,742.20. This trade represents a 2.45% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Cameron Turtle also recently made the following trade(s):

• On Friday, May 1st, Cameron Turtle sold 15,000 shares of Spyre Therapeutics stock. The stock was sold at an average price of $71.37, for a total value of $1,070,550.00.
• On Wednesday, April 1st, Cameron Turtle sold 15,000 shares of Spyre Therapeutics stock. The stock was sold at an average price of $49.33, for a total value of $739,950.00.

Spyre Therapeutics Trading Up 6.7%

Spyre Therapeutics stock opened at $78.48 on Friday. Spyre Therapeutics, Inc. has a twelve month low of $13.93 and a twelve month high of $79.54. The stock’s fifty day simple moving average is $66.06 and its 200-day simple moving average is $45.72. The firm has a market capitalization of $6.82 billion, a P/E ratio of -37.73 and a beta of 3.05.

Spyre Therapeutics (NASDAQ:SYRE) last posted its quarterly earnings data on Tuesday, May 5th. The company reported ($0.74) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.66) by ($0.08). Sell-side analysts predict that Spyre Therapeutics, Inc. will post -2.79 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of SYRE. Optimize Financial Inc grew its stake in Spyre Therapeutics by 1.5% in the 4th quarter. Optimize Financial Inc now owns 25,331 shares of the company’s stock worth $830,000 after acquiring an additional 364 shares during the period. Mercer Global Advisors Inc. ADV grew its stake in shares of Spyre Therapeutics by 0.5% during the 3rd quarter. Mercer Global Advisors Inc. ADV now owns 106,664 shares of the company’s stock valued at $1,788,000 after buying an additional 522 shares during the period. Summit Securities Group LLC purchased a new stake in shares of Spyre Therapeutics during the 1st quarter valued at $28,000. California State Teachers Retirement System boosted its position in Spyre Therapeutics by 1.8% during the 2nd quarter. California State Teachers Retirement System now owns 33,201 shares of the company’s stock worth $497,000 after purchasing an additional 603 shares during the period. Finally, AQR Capital Management LLC boosted its position in Spyre Therapeutics by 4.5% during the 4th quarter. AQR Capital Management LLC now owns 17,820 shares of the company’s stock worth $584,000 after purchasing an additional 773 shares during the period. 80.39% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several equities analysts have issued reports on the company. Deutsche Bank Aktiengesellschaft raised their price objective on Spyre Therapeutics from $102.00 to $115.00 and gave the stock a “buy” rating in a report on Thursday. Leerink Partners raised their price objective on Spyre Therapeutics from $49.00 to $106.00 and gave the stock an “outperform” rating in a report on Monday, April 13th. JonesTrading increased their target price on shares of Spyre Therapeutics from $64.00 to $95.00 and gave the stock a “buy” rating in a research note on Friday, April 17th. Stifel Nicolaus increased their target price on shares of Spyre Therapeutics from $92.00 to $107.00 and gave the stock a “buy” rating in a research note on Wednesday, May 6th. Finally, Wedbush increased their target price on shares of Spyre Therapeutics from $65.00 to $80.00 and gave the stock an “outperform” rating in a research note on Monday, April 13th. Two research analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Buy” and an average target price of $91.33.

About Spyre Therapeutics

Spyre Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel immunotherapies for cancer. The company leverages proprietary protein engineering and biologics design platforms to create targeted molecules intended to enhance anti-tumor immune responses and inhibit tumor growth. Its preclinical pipeline comprises multiple candidate therapies for solid tumor and hematologic oncology indications.

Established by a team with deep expertise in protein design, immunology and translational research, Spyre Therapeutics collaborates with leading academic institutions and research organizations to accelerate its discovery efforts.